Polymorphisms in the FKBP5 gene are associated with attention deficit and hyperactivity disorder in Korean children

Kim, Hyung Jun; Jin, Han Jun

doi:10.1016/j.bbr.2021.113508

Cited by 2 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous clinical and preclinical studies have robustly observed FKBP5/FKBP51 to be a central mediator of childhood adversity and HPA axis dysfunction and other sequelae [ 108 - 110 ]. In addition, FKBP5 was associated with MDD [ 111 ], bipolar disorder [ 112 ], schizophrenia [ 113 ], posttraumatic stress disorder [ 114 , 115 ], attention deficit hyperactivity disorder (ADHD) [ 116 ], chronic pain [ 117 , 118 ] and metabolic dysfunction, insulin resistance and obesity [ 119 , 120 ]. A wealth of data from genetic, epigenetic, and postmortem data support the fact that increased FKBP5 expression is associated with the risk of mental disorders, and the manipulation of FKBP5 in preclinical studies leads to the normalization of impaired behavior [ 108 ].…”

Section: Fkbp5 Antagonists and Ketaminementioning

confidence: 99%

The HPA Axis as Target for Depression

Menke

2024

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a stress-related mental disorder with a lifetime preva- lence of 20% and, thus, is one of the most prevalent mental health disorders worldwide. Many studies with a large number of patients support the notion that abnormalities of the hypothalamus-pituitary- adrenal (HPA) axis are crucial for the development of MDD. Therefore, a number of strategies and drugs have been investigated to target different components of the HPA axis: 1) corticotrophin- releasing hormone (CRH) 1 receptor antagonists; 2) vasopressin V1B receptor antagonists, 3) glucocor- ticoid receptor antagonists, and 4) FKBP5 antagonists. Until now, V1B receptor antagonists and GR antagonists have provided the most promising results. Preclinical data also support antagonists of FKBP5, which seem to be partly responsible for the effects exerted by ketamine. However, as HPA axis alterations occur only in a subset of patients, specific treatment approaches that target only single components of the HPA axis will be effective only in this subset of patients. Companion tests that measure the function of the HPA axis and identify patients with an impaired HPA axis, such as the dexamethasone-corticotrophin-releasing hormone (dex-CRH) test or the molecular dexamethasone- suppression (mDST) test, may match the patient with an effective treatment to enable patient-tailored treatments in terms of a precision medicine approach.

show abstract

Section: Fkbp5 Antagonists and Ketaminementioning

confidence: 99%

The HPA Axis as Target for Depression

Menke

2024

View full text Add to dashboard Cite

show abstract

“…The T allele of rs7748266 is associated with an increased risk of attention deficit hyperactivity disorder (ADHD) in children (145), susceptibility to developing depressive symptoms (146), and decreased cortisol levels (111). Rs7748266 is also associated with an increased amygdala reaction in childhood emotional neglect by decreasing the basal cortisol levels (147).…”

Section: Rsmentioning

confidence: 99%

Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery

Malekpour,

Shekouh,

Safavinia

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

Stress-induced mental health disorders are affecting many people around the world. However, effective drug therapy for curing psychiatric diseases does not occur sufficiently. Many neurotransmitters, hormones, and mechanisms are essential in regulating the body's stress response. One of the most critical components of the stress response system is the hypothalamus-pituitary-adrenal (HPA) axis. The FKBP prolyl isomerase 51 (FKBP51) protein is one of the main negative regulators of the HPA axis. FKBP51 negatively regulates the cortisol effects (the end product of the HPA axis) by inhibiting the interaction between glucocorticoid receptors (GRs) and cortisol, causing reduced transcription of downstream cortisol molecules. By regulating cortisol effects, the FKBP51 protein can indirectly regulate the sensitivity of the HPA axis to stressors. Previous studies have indicated the influence of FKBP5 gene mutations and epigenetic changes in different psychiatric diseases and drug responses and recommended the FKBP51 protein as a drug target and a biomarker for psychological disorders. In this review, we attempted to discuss the effects of the FKBP5 gene, its mutations on different psychiatric diseases, and drugs affecting the FKBP5 gene.

show abstract

Polymorphisms in the FKBP5 gene are associated with attention deficit and hyperactivity disorder in Korean children

Cited by 2 publications

References 42 publications

The HPA Axis as Target for Depression

The HPA Axis as Target for Depression

Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery

Contact Info

Product

Resources

About